TMC1 and hearing loss disorder: Among the reports excluded, nine studies may have appeared to meet the inclusion criteria as they related to gene therapies for the genetic form of sensorineural hearing loss However, (1) the study by Solanes P. et al. reporting that the delivery of CRISPR/Cas9 using AAV-PHP.B in mutated Tmc1 Beethoven mice protects auditory function was excluded because it targeted the autosomal dominant (DFNA36) and not the recessive (DFNB7/11) form of non-syndromic sensorineural hearing loss [16].